» Articles » PMID: 32498398

Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Jun 6
PMID 32498398
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

To date, lateral differences of invasive breast cancer (IBrC) with respect to the angiogenic and hemostatic profiles were never studied. Here, we aimed to determine the relationship of tumor laterality with various clinical and pathological parameters including angiogenic and hemostatic profiles. A total of 92 women that were initially non-metastatic and treated by surgery were included in this single-center prospective study. Patients were grouped according to tumor localization. A four-year follow-up was accomplished in all patients with a 15.22% recurrence rate. An immunoassay of selected angiogenic and hemostatic parameters, as well as immunohistochemistry of estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), and Ki67, was comparatively performed in groups with right- and left-sided IBrC. The same analysis was carried out in a subgroup of patients with luminal A molecular subtype of cancer. Patients with right-sided tumors free of nodal involvement had a significantly longer overall survival compared to their left-sided counterparts ( = 0.0491). Additionally, right-sided tumors had a higher predisposition to be a luminal-A subtype of IBrC ( = 0.0016). Furthermore, 10% of left-sided tumors exhibited an overexpression of HER2, while only 2% patients suffering right-sided tumors displayed a positive score ( = 0.0357). Our findings revealed a significantly higher concentration of vascular endothelial growth factor (VEGF)-A ( = 0.0136), lower anti-angiogenic ratios (sVEGFR1/VEGF-A ( = 0.0208) and sVEGFR2/VEGF-A ( = 0.0068)), and elevated plasminogen activator inhibitor type 1 (PAI-1) ( = 0.0229) in patients with breast cancer localized in the left breast, regardless of the molecular subtype of IBrC. Our study showed that left-sided breast tumors without lymph node metastases demonstrate worse overall survival. Laterality of IBrC is associated with pro-angiogenic and pro-thrombotic conditions. We propose to consider laterality as a prognostic factor of IBrC.

Citing Articles

Impacts of (rs10719) and (rs3742330) Variants on Breast Cancer Risk and Their Distribution in Blood and Tissue Samples of Egyptian Patients.

Shaalan A, Al Ageeli E, Kattan S, Almars A, Babteen N, Sindi A Curr Issues Mol Biol. 2024; 46(9):10087-10111.

PMID: 39329954 PMC: 11430749. DOI: 10.3390/cimb46090602.


Asymmetries of Left and Right Adrenal Glands in Neural Innervation and Glucocorticoids Production.

Saxu R, Yang Y, Gu H Int J Mol Sci. 2023; 24(24).

PMID: 38139285 PMC: 10743655. DOI: 10.3390/ijms242417456.


Current Cardioprotective Strategies for the Prevention of Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients.

Nikovia V, Chinis E, Gkantaifi A, Marketou M, Mazonakis M, Charalampakis N J Pers Med. 2023; 13(7).

PMID: 37511651 PMC: 10381791. DOI: 10.3390/jpm13071038.


Clinicopathological characteristics and survival outcomes in patients with angiosarcoma of breast.

Li J, Li Y, Wang Y, Li Z, Zhang H, Gao Y Cancer Med. 2023; 12(12):13397-13407.

PMID: 37143261 PMC: 10315782. DOI: 10.1002/cam4.6042.


Delineation of Pathogenomic Insights of Breast Cancer in Young Women.

Paul A, George B, Saini S, Pillai M, Toi M, Costa L Cells. 2022; 11(12).

PMID: 35741056 PMC: 9221490. DOI: 10.3390/cells11121927.


References
1.
Aoyagi Y, Iinuma H, Horiuchi A, Shimada R, Watanabe T . Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. Oncol Lett. 2012; 1(2):253-259. PMC: 3436373. DOI: 10.3892/ol_00000045. View

2.
Rutter C, Chagpar A, Evans S . Breast cancer laterality does not influence survival in a large modern cohort: implications for radiation-related cardiac mortality. Int J Radiat Oncol Biol Phys. 2014; 90(2):329-34. DOI: 10.1016/j.ijrobp.2014.06.030. View

3.
Wang Y, Sang A, Zhu M, Zhang G, Guan H, Ji M . Tissue factor induces VEGF expression via activation of the Wnt/β-catenin signaling pathway in ARPE-19 cells. Mol Vis. 2016; 22:886-97. PMC: 4961466. View

4.
Scutt D, Lancaster G, Manning J . Breast asymmetry and predisposition to breast cancer. Breast Cancer Res. 2006; 8(2):R14. PMC: 1557716. DOI: 10.1186/bcr1388. View

5.
Darby S, Cutter D, Boerma M, Constine L, Fajardo L, Kodama K . Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010; 76(3):656-65. PMC: 3910096. DOI: 10.1016/j.ijrobp.2009.09.064. View